Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Knee extensor muscle strength predicts ability to exercise in elderly HF patients

09 Jan 2020

In elderly heart failure (HF) patients, knee extensor muscle strength appears to be an important determinant of exercise capacity, particularly in those with sarcopoenia, reports a recent study.

Researchers measured the 6-minute walking distance (6MWD) in 186 consecutive elderly patients with HF (mean age, 79.8±9.64 years; 105 females). None of the participants had documented physical disability. Knee extensor muscle strength was measured using a hand-held dynamometer, placed on the participant’s ankle and fastened to a table leg. Extensions were performed twice for each leg.

Seventy-seven participants were found to have sarcopoenia, yielding a prevalence rate of 41.3 percent. Ninety-two percent had New York Heart Association functional class III at baseline.

Multiple regression analysis found that walking speed was significantly predictive of 6MWD (B, 243.943±19.595; p<0.001), as were age (B, –1.542±0.614; p=0.013) and calf circumference (B, 2.914±1.411; p=0.041).

Knee extensor muscle strength likewise emerged as a factor significantly and positively correlated with 6MWD (B, 15.225±3.874; p<0.001). This effect was only evident and significant in those with sarcopoenia (B, 14.139±6.08; p=0.023). Walking speed also emerged as an independent determinant of 6MWD in both patient subgroups.

“To our knowledge, this study is the first report to demonstrate the relationship between the 6MWD and muscle strength in elderly patients with HF with and without sarcopoenia,” said researchers.

“[O]ur findings add new and meaningful information regarding the exercise prescription for improving the 6MWD. Resistance training appears to be the primary exercise intervention for patients with HF with sarcopoenia,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.